Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that indicate the presence of cancer, enabling physicians to make quick, noninvasive diagnoses.
One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.